“Increasing Adoption of Deferasirox for Iron Overload Treatment”
One specific trend driving the growth of the deferasirox market is its increasing adoption for the treatment of iron overload, particularly in patients with thalassemia and sickle cell disease. As these conditions often require regular blood transfusions, which lead to iron buildup, deferasirox has become a key oral chelation therapy to manage this issue. Its convenience compared to traditional iron chelators, such as deferoxamine (which requires injection), has made it more appealing to both patients and healthcare providers. The growing awareness of iron overload complications and advancements in healthcare accessibility are contributing to the rising demand for deferasirox, expanding its market share globally.
